Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.64 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29409918 | 1.00 | LRRK2 (0.64) | LRRK2ALKINSRIGF1RMAP3K9 | |
| SCHEMBL29409854 | 0.94 | LRRK2 (0.70) | LRRK2ALKINSRMAP3K9MKNK2 | |
| SCHEMBL24556864 | 0.94 | LRRK2 (0.70) | LRRK2ALKINSRMAP3K9MKNK2 | |
| SCHEMBL29409864 | 0.92 | LRRK2 (0.54) | LRRK2ALKINSRIGF1RPTK2 | |
| SCHEMBL22658452 | 0.92 | LRRK2 (0.54) | LRRK2ALKINSRIGF1RPTK2 | |
| SCHEMBL22658873 | 0.92 | LRRK2 (0.65) | LRRK2ALKINSRIGF1RPTK2 | |
| SCHEMBL22658727 | 0.92 | LRRK2 (0.54) | LRRK2ALKINSRIGF1RPTK2 | |
| SCHEMBL29409914 | 0.92 | LRRK2 (0.54) | LRRK2ALKINSRIGF1RPTK2 | |
| SCHEMBL29409917 | 0.92 | LRRK2 (0.65) | LRRK2ALKINSRIGF1RPTK2 | |
| SCHEMBL22658732 | 0.91 | LRRK2 (0.55) | LRRK2ALKINSRIGF1RPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204515-A1 | PYRROLOPYRIMIDINE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204515-A1 | PYRROLOPYRIMIDINE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LRRK2, PARK7, PINK1 | LRRK2 1/4885ALK 4233/4885INSR 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.